Human monoclonal antibodies against bacterial toxins
AssigneeUniversity of Rochester
InventorsRichard A. Insel, Francis Gigliotti
Life of this patent
Estimating the term…
Abstract
The production of stable hybrid cell lines that secrete human monoclonal antibodies against bacterial toxins by fusing post-immunization human peripheral blood lymphocytes with nonsecretor mouse myeloma cells is described. Using the method, protective monoclonal antibodies against tetanus toxin and diphtheria toxin were produced that bind tetanus toxin and diphtheria toxin in vitro, respectively, and prevent tetanus and diphtheria in vivo in animals, respectively.
Claims10
A continuous cell line which produces human anti-exotixin antibodies, comprising:
- a stable fused cell hybrid of a human peripheral blood lymphocyte immunized by a toxin, or an imunogenic fragment thereof, or a toxoid prepared from an exotoxin, or an immunogenic fragment thereof, and a mouse myeloma cell, in which the antibodies are capable of neutralizing exotoxin.
A continuous cell line which produces human anti-endotoxin antibodies, comprising:
- a stable fused cell hybrid of a human peripheral blood lymphocyte immunized by a toxin, or an imunogenic fragment thereof, or a toxoid prepared from an endotoxin, or an immunogenic fragment thereof, and a mouse myeloma cell, in which the antibodies are capable of neutralizing endotoxin.
A continuous cell line which produces human anit-tetanus toxin antibodies, comprising:
- a stable fused cell hybrid of a tetanus toxin-immunized or toxoid-immunized human peripheral blood lymphocyte and a mouse myeloma cell, in which the anitbodies are capable of neutralizing tetanus toxin.
A continuous cell line which produces human anti-diphtherial toxin antibodies, comprising:
- a stable fused cell hydrid of a diphtheria toxin-immunized or toxoid-immunized human peripheral blood lymphocyte and a mouse myeloma cell, in which the antibodies are capable of neutralizing diphtheria toxin.
A continuous cell line which produces human anti-exotoxin antibodies, comprising:
- a stable fused cell hybrid of a human peripheral blood lymphocyte obtained from an individual and subsequently stimulate in vitro with a bacterial exotoxin, or an immunogenic fragment thereof, or and exotoxoid, or an immunogenic fragment thereof, and a mouse myeloma cell, in which the anitbodies are capable of neutralizing exotoxin.
A continuous cell line which produces human anti-endotoxin antibodies, comprising:
- a stable fused cell hybrid of a human peripheral blood lymphocyte obtained from an individual and subsequently stimulated in vitro with a bacterial endotoxin, or an immunogenic fragment thereof, or an endotoxoid, or an immunogenic fragment thereof, and a mouse myeloma cell, in which the anitbodies are capable of neutralizing endotoxin.
A continuous cell line which produces human anit-tetanus toxin antibodies, comprising:
- a stable fused cell hybrid of a human peripheral blood lymphocyte stimulated in vitro with tetanus toxin, or an immunogenic fragment thereof, or tetanus toxoid, or an immunogenic fragment thereof, and a mouse myeloma cell, in which the antibodies are capable of neutralizing tetanus toxin.
A continuous cell line which produces human anti-diphtheria toxin antibodies, comprising:
- a stable fused cell hybrid of a human peripheral blood lymphocyte stimulated in vitro with diphtheria toxin, or an immunogenic fragment thereof, or diphtheria toxoid or an immunogenic fragment thereof and a mouse myeloma cell, in which the antibodies are capable of neutralzing diphtheria toxin.
Cell line 9F12.
Cell line 16M3F10.
Dependencies are inferred from the claim text.